NATURAL PRODUCT COMMUNICATIONS

An International Journal for Communications and Reviews Covering all Aspects of Natural Products Research



www.naturalproduct.us



Natural Product Communications

EDITOR-IN-CHIEF

DR. PAWAN K AGRAWAL

Natural Product Inc. 7963, Anderson Park Lane, Westerville, Ohio 43081, USA agrawal@naturalproduct.us

EDITORS

PROFESSOR ALEJANDRO F. BARRERO Department of Organic Chemistry, University of Granada, Campus de Fuente Nueva, s/n, 18071, Granada, Spain afbarr@ugr.es PROFESSOR ALESSANDRA BRACA

Dipartimento di Chimica Bioorganicae Biofarmacia, Universita di Pisa, via Bonanno 33, 56126 Pisa, Italy braca@farm.unipi.it

PROFESSOR DEAN GUO State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China gda5958@163.com

PROFESSOR YOSHIHIRO MIMAKI

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachioji, Tokyo 192-0392, Japan mimakiy@ps.toyaku.ac.jp

PROFESSOR STEPHEN G. PYNE Department of Chemistry

University of Wollongong Wollongong, New South Wales, 2522, Australia spyne@uow.edu.au

PROFESSOR MANFRED G. REINECKE

Department of Chemistry, Texas Christian University, Forts Worth, TX 76129, USA m.reinecke@tcu.edu

PROFESSOR WILLIAM N. SETZER

Department of Chemistry The University of Alabama in Huntsville Huntsville, AL 35809, USA wsetzer@chemistry.uah.edu

PROFESSOR YASUHIRO TEZUKA *Institute of Natural Medicine*

Institute of Natural Medicine, University of Toyama, 2630-Sugitani, Toyama 930-0194, Japan tezuka@inm.u-toyama.ac.jp

PROFESSOR DAVID E. THURSTON

Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WCIN 1AX, UK david.thurston@pharmacy.ac.uk

HONORARY EDITOR

PROFESSOR GERALD BLUNDEN The School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT U.K. axuf64@dsl.pipex.com

ADVISORY BOARD

Prof. Berhanu M. Abegaz Gaborone, Botswana Prof. Viqar Uddin Ahmad Karachi, Pakistan Prof. Øyvind M. Andersen Bergen, Norway Prof. Giovanni Appendino Novara, Italy Prof. Yoshinori Asakawa Tokushima, Japan Prof. Lee Banting Portsmouth, U.K. Prof. Julie Banerji Kolkata, India Prof. Anna R. Bilia Florence, Italy Prof. Maurizio Bruno Palermo, Italy Prof. César A. N. Catalán Tucumán, Argentina Prof. Josep Coll Barcelona, Spain Prof. Geoffrey Cordell Chicago, IL, USA Prof. Ana Cristina Figueiredo Lisbon, Portugal Prof. Cristina Gracia-Viguera Murcia, Spain Prof. Duvvuru Gunasekar Tirupati, India Prof. Kurt Hostettmann Lausanne, Switzerland Prof. Martin A. Iglesias Arteaga Mexico, D. F. Mexico Prof. Jerzy Jaroszewski Copenhagen, Denmark Prof. Leopold Jirovetz Vienna, Austria

Prof. Karsten Krohn Paderborn, Germany Prof. Hartmut Laatsch Gottingen, Germany Prof. Marie Lacaille-Dubois Dijon, France Prof. Shoei-Sheng Lee Taipei, Taiwan Prof. Francisco Macias Cadiz. Spain Prof. Imre Mathe Szeged, Hungary Prof. Joseph Michael Johannesburg, South Africa Prof. Ermino Murano Trieste, Italy Prof. M. Soledade C. Pedras Saskatoon, Canada Prof. Luc Pieters Antwerp, Belgium Prof. Peter Proksch Düsseldorf, Germany Prof. Phila Raharivelomanana Tahiti, French Polynesia Prof. Luca Rastrelli Fisciano, Italy Prof. Monique Simmonds Richmond, UK Prof. John L. Sorensen Manitoba, Canada Prof. Valentin Stonik Vladivostok, Russia Prof. Winston F. Tinto Barbados, West Indies Prof. Sylvia Urban Melbourne, Australia Prof. Karen Valant-Vetschera Vienna, Austria

INFORMATION FOR AUTHORS

Full details of how to submit a manuscript for publication in Natural Product Communications are given in Information for Authors on our Web site http://www.naturalproduct.us.

Authors may reproduce/republish portions of their published contribution without seeking permission from NPC, provided that any such republication is accompanied by an acknowledgment (original citation)-Reproduced by permission of Natural Product Communications. Any unauthorized reproduction, transmission or storage may result in either civil or criminal liability.

The publication of each of the articles contained herein is protected by copyright. Except as allowed under national "fair use" laws, copying is not permitted by any means or for any purpose, such as for distribution to any third party (whether by sale, loan, gift, or otherwise); as agent (express or implied) of any third party; for purposes of advertising or promotion; or to create collective or derivative works. Such permission requests, or other inquiries, should be addressed to the Natural Product Inc. (NPI). A photocopy license is available from the NPI for institutional subscribers that need to make multiple copies of single articles for internal study or research purposes.

To Subscribe: Natural Product Communications is a journal published monthly. 2012 subscription price: US\$1,995 (Print, ISSN# 1934-578X); US\$1,995 (Web edition, ISSN# 1555-9475); US\$2,495 (Print + single site online); US\$595 (Personal online). Orders should be addressed to Subscription Department, Natural Product Communications, Natural Product Inc., 7963 Anderson Park Lane, Westerville, Ohio 43081, USA. Subscriptions are renewed on an annual basis. Claims for nonreceipt of issues will be honored if made within three months of publication of the issue. All issues are dispatched by airmail throughout the world, excluding the USA and Canada.

NPC Natural Product Communications

Synthesis and Biological Evaluation of Combretastatin A-4 and Three Combretastatin-Based Hybrids

Miguel A. González^{a,*}, David Pérez-Guaita^a, Lee S. Agudelo-Goméz^b, Verónica Tangarife-Castaño^b, Bibiana Zapata^b and Liliana Betancur-Galvis^{b,**}

^aDepartment of Organic Chemistry, University of Valencia, Burjassot E-46100, Valencia, Spain ^bGroup of Investigative Dermatology, University of Antioquia, Medellín A.A1226, Antioquia, Colombia

*Chemical aspects: miguel.a.gonzalez@uv.es **Biological aspects: betancurli@hotmail.com

Received: March 24th, 2012; Accepted: May 17th, 2012

The syntheses of combretastatin A-4 from gallic acid and of three combretastatin-based hybrids are described. Starting from commercial gallic acid, the phosphonium salt (3,4,5-trimethoxybenzylphosphonium bromide) is synthesized and coupled, through a Wittig reaction, with several aldehydes, including methoxymethyl-protected isovanillin, the aldehyde γ -bicyclohomofarnesal having a labdane skeleton, 3-(3-pyridyl) propanal, and furfural. The biological properties of the *cis*-coupled compounds as cytotoxic, antiviral and antifungal agents are also reported. In addition, pyrogallol, gallic and 3,4,5-trimethoxybenzoic acids have been studied biologically.

Keywords: Combretastatin A-4, Gallic acid, Pyrogallol, Antifungal activity, Cytotoxic activity, Antiviral activity.

Combretastatin A-4 (CA-4, 1) (Figure 1) is isolated from the African willow tree *Combretum caffrum* and has been known for over 20 years ago [1]. It is a strong tubulin depolymerizing agent and, therefore, inhibits tumor growth and has antivascular effects [2]. Its prodrug (disodium salt, water-soluble phosphate derivative, CA-4P, 2) has entered clinical trials for both solid and liquid tumors [3]. Similarly, a close derivative of CA-4 (AVE-8062, 3) is also undergoing clinical trials [4]. Both compounds have demonstrated a sufficient safety profile in phase I trials, suggesting that this may be a viable therapeutic strategy.



Figure 1: Tubulin polymerization inhibitors.

Despite its low molecular weight and simple molecular structure, CA-4 is one of the most powerful inhibitors of tubulin polymerization known to date. The structure can be divided into three separate components, the two rings (usually termed A and B) and the olefinic bridge. The structure-activity relationship (SAR) of CA-4 has been investigated thoroughly by a number of groups, being reasonably well-understood, and medicinal chemistry has been largely explored on its carbon framework [5]. In brief, it is thought that the cis-configuration of the olefinic bridge, the presence of the 3,4,5-trimethoxy group on ring A, and the paramethoxy group on ring B are fundamental for antitubulin activity. However, active compounds not obeying this general rule have been described [6]. Thus, modifications of the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors. Among these derivatives, a number of combretastatinbased hybrids have been the objective of several research groups, for example, the synthesis and biological properties of combretastatin-based hybrids with colchicines [7], lamellarins [8], chromone [9], and chalcone [10]. On the basis of this motivation, in this study, and based on our prior experience with other bioactive



Figure 2: Designed combretastatin-based hybrids, parent carbon frameworks and other tested molecules

molecules, we planned to select the 3,4,5-trimethoxybenzene and the *cis*-olefinic bridge moieties present in CA-4 as the core structure. Therefore, in this study we have combined important pharmacophore structures of combretastatins with bioactive carbon frameworks to design several hybrids, which have been studied as cytotoxic, antiviral and antifungal agents (Figure 2). In addition, pyrogallol (12), gallic acid (13) and 3,4,5-trimethoxybenzoic acid (14) (trimethylgallic acid) have also been studied biologically.

As parent carbon frameworks to combine with the 3,4,5trimethoxybenzene moiety through a *cis*-olefinic bridge, we have chosen two terpenoid skeletons that have shown a high bioactive profile, abietic acid (4) [11], and the natural dialdehyde belonging to the labdane class of terpenoids, labdadienedial (5) (Figure 2) [12]. Also, we wanted to introduce a 3-alkylpyridine moiety, which is present in natural bioactive pyridine alkaloids 6, as antineoplastic theonelladin A and anti-microfouling untenine A [13]. Finally, we wanted to introduce a furan ring, through furfural 7, to see the influence of this on bioactivity. Our retrosynthesis towards CA-4 and the combretastatin-based hybrids focused on the Wittig reaction (Scheme 1) between the known phosphonium salt, 3,4,5-trimethoxybenzylphosphonium bromide (18) [14], which was synthesized from gallic acid (13), and several readily available aldehydes, such as methoxymethylprotected isovainillin 20 (Scheme 2) [15], and the aldehyde abietinal (23), prepared from abietic acid [11], the aldehyde γ bicyclohomofarnesal (26) prepared from (+)-sclareolide [16], 3-(3pyridyl)propanal (28) prepared by Dess-Martin oxidation of 3-(3pyridyl) propanol (27) [13b], and commercial furfural 7. Aldehydes 23 and 26 are known intermediates in the synthesis of different terpenoid systems and both can be prepared in three steps starting from commercial (-)-abietic acid and commercial (+)-sclareolide, respectively [11,12]. The key Wittig reaction with ylide derived from phosphonium salt 18 has precedent in the literature, and has already been reported with different protecting groups in the aldehyde counterpart in the synthesis of combretastatin A-4 [17]. Thus, the introduction of the 3,4,5-trimethoxybenzene and cis-olefin moieties to obtain CA-4 was easy, but, the introduction of these moieties into other aldehyde systems represented a challenge for us.

The synthesis began with the alkylation and esterification of gallic acid (13) using dimethyl sulfate in basic media to afford trimethoxyester (methyl 3,4,5-trimethoxybenzoate) 15 (80%) (Scheme 1).



Reagents: a)Me₂SO₄,NaOH; b)LiAIH₄, THF; c)CBr₄,PPh₃; d) PPh₃,PhMe

Scheme 1: Retrosynthesis of the combretastatin-based hybrids and synthesis of the phosphonium salt 18 from gallic acid [13].

The control of the esterification step led to the isolation of trimethylgallic acid (92%, 14) as intermediate. Then, reduction of the ester in 15 with LiAlH₄ in THF gave the corresponding benzyl alcohol 16 in 88% yield, which was converted to its corresponding bromide 17 (80%) by reaction with CBr_4/PPh_3 in DCM. Finally, treatment of bromide 17 with triphenylphosphine in refluxing toluene led to the key phosphonium salt 18 in quantitative yield (Scheme 1) [14].

Next, we carried out the synthesis of the necessary aldehydes for the Wittig reaction with the ylide derived from phosphonium salt 18 (Scheme 2). First, we protected commercial isovanillin (19) as its corresponding methoxymethyl ether using MOMCl/K₂CO₃ to afford MOM-ether 20 in 76% yield [15]. Abietic acid (4) was esterified by treatment with lithium hydroxide and dimethyl sulfate to give ester 21 in quantitative yield. Reduction of ester 21 with LiAlH₄ in dry tetrahydrofuran under reflux gave alcohol (abietinol) 22 in quantitative yield. Oxidation of 22 was carried out by treatment with PCC on alumina [18]. This oxidation afforded the desired aldehyde (abietinal) 23 in 40% yield [11]. Next, we synthesized the aldehyde γ -bicyclohomofarnesal (26) from commercially available (+)-sclareolide. Thus, (+)-sclareolide was reacted with the dimethylaluminum amide derived from N-methoxy-N-methylamine yielding the desired Weinreb's amide 24 in 85% yield (Scheme 2). The tertiary alcohol of amide 24 was dehydrated in the presence of SOCl₂/pyridine at -78°C to give essentially the exo-isomer 25 in 90% yield. Finally, compound 25 was treated with DIBAL-H



Reagents: a) MOMCI, K₂CO₃; b) Me₂SO₄, LiOH; c) LiAIH₄, THF; d)PCC/AI₂O₃; e) MeONHMe.HCl, AIMe₃; f) SOCl₂/py; DIBAL-H; h) Dess-Martin periodinane.

Scheme 2: Synthesis of aldehydes 20, 23, 26, and 28.

at -78°C to give the desired aldehyde **26_in** 92% yield [12]. 3-Pyridinepropanol **27** was oxidized with Dess-Martin periodinane to give the desired 3-pyridinepropanal **28** in 96% yield. Commercial furfural (**7**) was used as received without purification.

With the aldehydes 7, 20, 23, 26, and 28 in hand, our next objective was to accomplish the key Wittig reaction to introduce the 3,4,5trimethoxybenzene and cis-olefinic bridge moieties. The necessary ylide derived from phosphonium salt 18 was generated with butyllithium in THF at -30°C prior to the addition of the different aldehvdes at this temperature and then allowing the mixture to warm to room temperature slowly. All reactions worked giving the corresponding cis-stilbenes 9-11 and MOM-protected CA-4, after careful silica gel column chromatography, with good yields (65-90%) and Z:E (ratio ca. 2:1 to 4:1) selectivity, except for the reaction with abietinal 23 to afford 8 that failed, probably due to steric hindrance present in the reacting aldehyde group. Combretastatin A-4 (1) was obtained after deprotection of the MOM-protected molecule with refluxing acetic acid in water (8:2) (90%). Compounds 1 and 11 are previously known [1,19], while 9 and 10 are new.

The combretastatin-based hybrids 9-11, combretastatin A-4 (1) itself, and compounds 12-14 were tested in vitro for potential antitumor and cytotoxic activities by determining the concentration of the compound that induces 50% growth inhibition (IC₅₀) on the HeLa tumor cell line and non-tumor Vero cell line, respectively (Table 1). The antitumor activity on HeLa cells, and cytotoxic activity on Vero cells have been carried out using the tetrazoliumdve (MTT) assay in vitro on cell growth according to the protocol reported by us [20], which was used with a few modifications. Vincristine was used as positive control. All these compounds produced a dose-dependent inhibition of the growth of cell lines, with R^2 (coefficient of linear regression) > 0.8. The derivatives 1, 11 and 12 showed in vitro potential antitumor activity. The combretastatin-hybrid 11 with a furan ring showed the highest potential antitumor activity on the HeLa tumor line with an IC₅₀ value of $3.0 \pm 0.5 \ \mu\text{g/mL}$. However, the compound with the highest selectivity index (SI) was pyrogallol (12). The susceptibility of tumor cell lines to pyrogallol has also been exhibited for A549 lung cancer cells and its non-cytotoxicity to MRC-5 normal lung fibroblasts [21]. Selectivity refers to the ability of a compound to

Table 1: Cytotoxic activity of compounds 1, 9-14 determined by the MTT technique expressed as $\rm IC_{50}~(\mu g/mL).^a$

		Cell In	ne		
Compound	HeLa ^b		Ver	Vero ^c	
	CC ₅₀	R ^{2,d}	IC 50	\mathbf{R}^2	SI ^e
1	6.3±3.3	0.7	30.7±0.7	1.0	4.9
9	15.1±1.6	0.9	26.4±5.3	0.7	1.8
10	15.9±1.9	0.9	106.2±3.9	1.0	6.7
11	3.0±0.5	0.8	28.9±5.2	0.8	9.6
12	4.1±1.2	0.8	120.0±12.6	0.9	29.4
13	21.3±1.1	1.0	39.9±4.3	0.9	1.9
14	39.6±5.2	1.0	>200		>5.05
Vincristine	0.05±0.01	1.0	1.1±0.2	1.0	22

^a Concentration of compounds which induces 50% growth inhibition in 48 h. ^b HeLa, human cervix epithelial carcinoma; ^c Vero, *Cercopithecus aethiops* African green monkey kidney; ^d*R*²: coefficient of linear regression. ^eSI, selectivity index is defined as Vero IC₅₀ over HeLa IC₅₀.

recognize its target without interacting with other targets. Recently, an SI value of 14.3 on cell lines is indicative of potential antitumor activity for biopharmaceutical use [22]. Therefore, the combretastatin- hybrid **11** with a SI value of 9.63 could be a possible antitumor agent.

All compounds 1, 9-14 were tested for anti-Candida, anti-Aspergillus, anti-Fusarium and anti-dermatophyte activity. The antifungal activity was evaluated following the standard method proposed by the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST EUCAST) [23] for fermentative yeasts and the Clinical and Laboratory Standards Institute M38-A (CLSI M38-A, 2002) protocol [24] for filamentous fungi, which was used with a few modifications. The yeast C. parapsilosis (ATCC 22019), C. krusei (ATCC 6258), C. tropicalis (CECT 11901), C. albicans (ATCC 10231) and the filamentous fungi Aspergillus fumigatus (ATCC 204305), A. flavus (ATCC 204304), A. terreus (CDC 317), Fusarium oxysporum (ATCC 48112), and the dermatophytes Trichophyton rubrum (ATCC 28188) and T. mentagrophytes (ATCC 24198) were used to evaluate antifungal activity. Amphotericin B (AMB), itraconazole (ITZ) and terbinafine (TERB) were used as positive controls with Candida spp., Aspergillus spp. and dermatophytes species, respectively, where the MIC values for the three reference drugs were within the established values for the standard protocols (Table 2). The compounds did not show activity against Candida parapsilopsis, C. krusei, C. tropicalis, C. albicans, Aspergillus flavus and Fusarium oxysporum at concentrations lower than 100.0 µg/mL, except the pyrogallol compound 12 that showed MIC values of $6.25 \pm 0 \,\mu\text{g/mL}$, $25.0 \pm 0 \,\mu\text{g/mL}$, $79.4 \pm 25.8 \,\mu\text{g/mL}$, $100 \pm 0 \ \mu g/mL$, $396.9 \pm 129.1 \ \mu g/mL$ and $79.4 \pm 28.9 \ \mu g/mL$, respectively (data not shown). Moreover, the combretastatin-based hybrid 9 and compound 14 did not show activity against any fungi evaluated (Table 2).

Studies of antifungal activity against *Candida*, *Aspergillus*, *Fusarium* and dermatophyte species of pyrogallol have not been reported so far. Furthermore, in previous studies, Pettit *et al.*[25] did not find anti-*Candida* activity for combretastatin A-4 (1), however, a combretastatin-hybrid with a nitroethylene moiety, the 3,4,5-trimethoxy- β -nitrostyrene, showed activity against *C. albicans* ATCC 90028 (MIC = 32.0 µg/mL). In this study, pyrogallol (12) also showed MIC values of 396.8 ± 129.1 µg/mL against *A. fumigates*, 31.5 ± 14.4 µg/mL against *A. terreus* and 25 ± 0 µg/mL against *T. rubrum* and *T. mentagrophytes*. In addition, gallic acid (13) had activity against *T. rubrum* and *T. mentagrophytes* (MIC = 50.0 ± 0 µg/mL and 39.7± 12.9 µg/mL, respectively). Moreover, the combretastatin-based hybrid 11 and combretastatin A-4 (1) showed MIC values much lower than those of compounds

Table 2: Antifungal activ	ty of compounds	1, 9-14 expressed as	MIC values in µg/mL ^a
---------------------------	-----------------	----------------------	----------------------------------

			GM-MIC (µg/mL) ^a		
Compound	A. fumigatus (ATCC 204305)	A. terreus (CDC 317)	Trichophyton rubrum (ATCC 28188)	Trichophyton mentagrophytes (ATCC 24198)	
1	50 ± 0	>100	19.8 ± 6.5	15.8± 6.5	
9	>100	>100	>100	>100	
10	50 ± 34.2	>100	100 ± 0	50± 0	
11	19.8 ± 6.5	63 ± 25.8	15.7 ± 6.8	15.8 ± 6.5	
12	396.9 ± 129.1	31.5 ± 14.4	25 ± 0	25 ± 0	
13	>100	>100	50 ± 0	39.69 ± 12.91	
14	>100	>100	>100	>100	
TERB			$<\!\!0.078 \pm 0$	$0,03125 \pm 0$	
AMB	2 ± 0	-	-	-	
ITZ	0.17 ± 0.1				
^a Geometric means of minimal inhibitory concentration of tested compounds in µg/mL.					

 Table 3: Antiviral activity: Cytotoxicity and anti-HHV-1/ HHV-2 activity of 1, and 9-14 on Vero Cells **determined by the end-point titration technique.

	HHV-1			HHV-2		
Compound	CC_{100} $(\mu g/mL)^{a}$	Viral Reduction Factor ^b	Antiviral Activity (µg/mL) ^c	Viral Reduction Factor ^b	Antiviral Activity (µg/mL) ^c	
1 (39)	100	100.5	50	10 ²	25	
9 (40)	25	10 ^{0.5}	12.5	10^{2}	3.125	
10 (47)	>50	10 ^{0.5}	50	N.A	N.A	
11 (43)	50	N.A	N.A	N.A	N.A	
12	>50	N.A	N.A	N.A	N.A	
13 (44)	>50	10 ¹	6,25	10 ²	6,25	
14 (41)	>200	N.A	N.A	N.A	N.A	
Heparin (I.U/mL)	>100	10^{2}	0.5	10 ²	0.5	
Acyclovir	> 600	10^{4}	6.0	10^{4}	6.0	

^{*a*} Minimal toxic dose that detached 100% of the cell monolayer. ^{*b*} ratio of the virus titer in the absence over virus titer in the presence of the tested compound. ^{*c*} maximal nontoxic dose that showed the highest viral reduction factor. N.A: no activity.

12 and 13 against *A. fumigatus* and the dermatophytes *Trichophyton rubrum* and *T. mentagrophytes*, the hybrid 11 showing the highest activity in all cases (MIC = $19.8 \pm 6.5 \ \mu g/mL$, $15.7 \pm 6.7 \ \mu g/mL$ and $15.7 \pm 6.4 \ \mu g/mL$, respectively). Furthermore, only the combrestastatin-hybrid 11 showed activity against *Aspergillus terreus* with an MIC value of $63.0 \pm 25.8 \ \mu g/mL$. It is important to note that *Aspergillus fumigatus* is the most important mold causing fungemia and is known to have high resistance to many antimycotic agents. On the other hand, dermatophytes are the most common etiological agents of the superficial fungal infection known as dermatophytosis, which affects skin, hair and nails. To the best of our knowledge, this is the first report of antifungal activity on *Aspergillus* spp. and dermatophyte species of combretastatin A-4 (1), combrestastatin-based hybrids, and gallic acid derivatives.

The antiviral activity of compounds **1**, **9-14** against Herpes simplex virus type 1 (HHV-1), obtained from the Center for Disease Control (Atlanta, GA) and HHV-2 (ATCC VR-734, strain G) was carried out on Vero cells using an end-point titration technique, according to the protocol reported by us [26], which was used with a few modifications [27]. Combretastatin A-4 and hybrid **9** showed activities against HHV, and reduced HHV-2 replication with concentrations below 25.0 and 3.1 μ g/mL, respectively (Table 3). Gallic acid (**13**) showed the highest antiviral activity for HHV-1 and HHV-2.

According to Vlietinck *et al.* [28], only compounds with a reduction factor (*Rf*) of the viral titer over 1 x 10^3 (Rf: ratio of the virus titer in the absence over virus titer in the presence of the tested compound) show relevant antiviral activity. Gallic acid (**13**) was found to be slightly active against HHV-1 and HHV-2 over infected confluent monolayers of Vero cells with an *Rf* value of 1x10¹ and 1x10² at a concentration of 6.25 µg/mL. Kratz *et al.* [29] have reported the activity of gallic acid and pentyl gallate against HHV-1 and HHV-2

[29,30]. This is the first time that anti-herpetic activity of combretastatin A-4 (1) and combrestastatin-based hybrids is described.

Experimental

Chemistry: Optical rotations were determined using a 5 cm pathlength cell, using dichloromethane as solvent (concentration expressed in g/100 mL). $[\alpha]_D$ -Values are given in 10⁻¹ deg cm²/g. NMR spectra were recorded on a 300 MHz spectrometer with tetramethylsilane as an internal standard. All spectra were recorded in CDCl₃, unless otherwise described. Complete assignments of ¹³C NMR multiplicities were made on the basis of DEPT experiments. J values are given in Hertz. Mass spectra (MS) were run by electron impact (EI) at 70 eV. Reactions were monitored by TLC using Merck silica gel 60 F-254 on 0.25 mm thick plates. Compounds on TLC plates were detected under UV light at 254 nm and visualized by immersion in a 10% sulfuric acid solution and heating on a hotplate. Purifications were performed by flash chromatography on Merck silica gel (230-400 mesh). All non-aqueous reactions were carried out in an argon atmosphere in oven-dried glassware. Commercial reagent grade solvents and chemicals were used as received unless otherwise noted. Combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.

All compounds gave satisfactory spectroscopical NMR data:

Compound 1

¹H NMR (300 MHz, CDCl₃) δ : 6.90 (1H, d, J = 1.8), 6.77 (1H, dd, J = 8.1, 1.8), 6.70 (1H, d, J = 8.4), 6.51 (2H, s), 6.44 (1H, d, J = 12.3), 6.37 (1H, d, J = 12.3), 5.80 (1H, br s), 3.82 (3H, s), 3.81 (3H, s), 3.66 (6H, s);

¹³C NMR (75 MHz, CDCl₃) δ: 152.8 (2 C), 145.8, 145.2, 137.1, 132.7, 130.6, 129.5, 128.9, 121.1, 115.1, 110.4, 106.0 (2 C), 60.9, 55.9 (3 C).

Compound 9

¹H NMR (300 MHz, CDCl₃) δ : 6.43 (2H, s), 6.17 (1H, d, J = 11.8), 5.44 (1H, ddd, J = 12.3, 6.6, 5.7), 4.71 (1H, s), 4.29 (1H, s), 3.75 (9H, s), 0.77 (3H, s), 0.71 (3H, s), 0.61 (3H, s).

¹³C NMR (75 MHz, CDCl₃) 8: 152.5 (2 C), 147.9, 136.4, 133.3, 132.9, 128.0, 107.6, 105.6 (2 C), 60.5, 57.2, 55.7 (2 C), 55.1, 41.8, 39.2, 39.1, 37.8, 33.3, 33.2, 23.9, 23.6, 21.5, 19.1, 14.3.

Compound 10

¹H NMR (300 MHz, CDCl₃) δ: 8.47 (2H, m), 7.51 (1H, m), 7.21 (1H, m), 6.56 (1H, s), 6.55 (1H, s), 6.17 (1H, m), 3.85 (6H, s), 3.84 (3H, s), 2.78 (2H, m), 2.52 (2H, m).

¹³C NMR (75 MHz, CDCl₃) δ: 153.1 (2 C), 152.7, 149.8, 136.6, 135.7, 133.0, 130.8, 128.3, 123.1, 105.5, 102.8 (2 C), 60.7, 55.8 (2 C), 34.2, 32.7.

Compound 11

¹H NMR (300 MHz, CDCl₃) δ : 7.33 (1H, br s), 6.74 (2H, s), 6.39 (1H, d, J = 12.8), 6.32 (1H, d, J = 12.6), 3.88 (3H, s), 3.83 (6H, s). ¹³C NMR (75 MHz, CDCl₃) δ : 153.3, 152.8 (2 C), 151.9, 141.5, 132.6, 127.8, 117.4, 111.3, 110.4, 105.8, 103.2, 60.9, 55.9 (2 C).

MTT Assay: The cells used were: Vero (African green monkey kidney, ATCC: CCL 81 line) and HeLa (human cervix epithelial carcinoma, ATCC CCL-2) cell lines. Initially, cells were kept in log phase of growth in MEM modified by Dulbecco (DMEM) supplemented respectively with 5% fetal bovine serum (SBF),

1µg/mL penicillin, streptomycin 1µg/mL, 1µg/mL of neomycin, vitamins, nonessential amino acids and 1% glutamine. The pH of 7.2 required for cell cultures was achieved with 1N sodium hydroxide, and stabilized with 0.5% aqueous sodium bicarbonate solution, 7%. Cell cultures were maintained at 37°C in a humidified 5% CO₂ atmospheric chamber. Then, cell monolayers were trypsinized and washed with culture medium and then plated at 1.5 x 10^4 cells per well for HeLa and 1.25 x 10^4 cells per well for Vero cells in 96-well flat-bottomed plates. After 24 h of incubation, each diluted compound was added to the appropriate wells and the plates were incubated for a further 48 h at 37°C in a humidified incubator with 5% CO2. Vincristine and pyrogallol were used as positive controls. The CC50 for each compound was obtained from doseeffect curves by linear regression methods and CC50 values are expressed as the mean \pm S.E.M. of least 4 dilutions, repeated 8 times.

Antifungal activity: The standard methods proposed by the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST EUCAST) [23] for fermentative yeasts and the Clinical and Laboratory Standards Institute M38-A (CLSI M38-A, 2002) [24] for filamentous were used with a few modifications. The dilutions of the compounds were dispensed into 96-well flat-bottom microdilution plates in duplicate at final concentrations between 100.0 µg/mL and 2.0 µg/mL. Amphotericin B (Sigma Chemical Co. MO, USA) with A. fumigatus and A. flavus, itraconazole (Sigma Chemical Co, MO, USA) with C. krusei and C. parapsilosis and terbinafine (Recalcine Laboratories, Santiago de Chile, Chile) with dermatophytes were used as positive controls at a range of 0.031-16.0 µg/mL. The inoculum sizes for microdilution plates were 0.5 -2.5 x 10^5 and 0.2- 2.5 x 10^5 CFU/mL for yeast and filamentous fungi, respectively. For the AFST-EUCAST method, the Minimal Inhibitory Concentrations (MICs) were determined after 24 h at 35°C of incubation by spectrophotometric reading at 405 nm and is defined as the lowest concentration that resulted in a 90% reduction of growth. For the CLSI M38-A method, the MICs were determined after 48 h of incubation at 35°C for Aspergillus spp. and at 28°C for F. oxysporum. The activity against the dermatophytes was determined after 6 days of incubation at 28°C. The MICs were defined as the lowest dilution that resulted in 80% inhibition of visible growth. MIC results were expressed as range and geometric mean (GM) of duplicates of each compound tested 3 times against each of the fungal species in different assays.

Antiviral activity: Herpes simplex virus types 1 and 2 were obtained from the Center for Disease Control (Atlanta, GA). Virus stocks (HHV-1 and HHV-2) were prepared from infected Vero cell cultures using an end-point titration technique. Two-fold dilutions of the compounds and viral suspension (one infection dose, 1 D.I.) were mixed and incubated for 0.5 h at 21°C before they were added onto confluent monolayer cells and incubated again at 37°C in a humidified 5% CO₂ atmosphere for 36 h. Acyclovir and heparin sodium salt were used as positive controls.

Acknowledgments - Financial support from the Spanish Ministry of Science and Education, under a "Ramón y Cajal" research grant, and also from the Generalitat Valenciana (project GV/2007/007) is gratefully acknowledged. L. B-G. thanks the financial support from Antioquia University of Colombia and COLCIENCIAS (Patrimonio Autónomo del Fondo Nacional de Financiamiento para la Ciencia, la Tecnología y la Innovación, Francisco José de Caldas), Bogotá, Colombia (Grant RC 366-2011).

References

- [1] Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendal D. (1989) Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. *Experientia*, 45, 209-211.
- (a) Bibby MC. (2002) Combretastatin anticancer drugs. Drugs Future, 27, 475-480; (b) Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. (2005) The discovery and development of the combretastatins. In Anticancer Agents from Natural Products. Kingston D, Newman D, Cragg G. (Eds). CRC Press: Boca Raton, F, 23-46; (c). Theeramunkong S, Caldarelli A, Massarotti A, Aprile S, Caprioglio D, Zaninetti R, Teruggi A, Pirali T, Grosa G, Cesare Tron G, Genazzani AA. (2011) Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. Journal of Medicinal Chemistry, 54, 4977-4986.
- (a) West CM, Price P. (2004) Combretastatin A4 phosphate. Anti-Cancer Drugs, 15, 179-187; (b) Siemann, DW, Chaplin DJ, Walicke PA. (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion on Investigational Drugs, 18, 189-197.
- [4] Delmonte A, Sessa C. (2009) AVE8062: a new combretastatin derivative vascular disrupting agent. *Expert Opinion on Investigational Drugs*, 18, 1541-1548.
- [5] (a) Nam NH. (2003) Combretastatin A-4 analogues as antimitotic antitumor agents. Current Medicinal Chemistry, 10, 1697-1722; (b) Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. (2006) Medicinal chemistry of combretastatin A4: present and future directions. Journal of Medicinal Chemistry, 49, 3033-3044; (c) Shan Y, Zhang J, Liu Z, Wang M, Dong Y. (2011) Developments of combretastatin A-4 derivatives as anticancer agents. Current Medicinal Chemistry, 18, 523-538.
- [6] (a) Gaukroger K, Hadfield JA, Lawrence NJ, Nolan S, McGown AT. (2003) Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Organic & Biomolecular Chemistry, 1, 3033-3037; (b) Beale TM, Myers RM, Shearman JW, Charnock-Jones DS, Brenton JD, Gergely FV, Ley SV. (2010) Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. MedChemComm, 1, 202-208.
- [7] Janik ME, Bane SL. (2002) Synthesis and antimicrotubule activity of combretatropone derivatives. *Bioorganic & Medicinal Chemistry*, 10, 1895-1903.
- [8] (a) Banwell MG, Hamel E, Hockless DC, Verdier-Pinard P, Willis AC, Wong DJ. (2006) 4,5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: synthesis and evaluation as anti-mitotic and cytotoxic agents. *Bioorganic & Medicinal Chemistry*, 14, 4627-4638; (b) Shen L, Yang X, Yang B, He Q, Hu Y. (2010) Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents. *European Journal of Medicinal Chemistry*, 45, 11-18.
- [9] Quintin J, Roullier C, Thoret S, Lewin G. (2006) Synthesis and anti-tubulin evaluation of chromone-based analogues of combretastatins. *Tetrahedron*, 62, 4038-4051.
- [10] Nam NH, Byung-Zun A. (2007) Combretastatin-chalcone hybrids: synthesis and cytotoxicity. Medicinal Chemistry, 3, 373-377.
- [11] González MA, Correa-Royero J, Agudelo L, Mesa A, Betancur-Galvis L. (2009) Synthesis and biological evaluation of abietic acid derivatives. European Journal of Medicinal Chemistry, 44, 2468-2472.
- [12] González MA, Pérez-Guaita D, Correa-Royero J, Zapata B, Agudelo L, Mesa-Arango A, Betancur-Galvis L. (2010) Synthesis and biological evaluation of dehydroabietic acid derivatives. *European Journal of Medicinal Chemistry*, 45, 4403-4408.
- [13] (a) Kobayashi J, Murayama T, Ohizumi Y, Sasaki T, Ohta T, Nozoe S. (1989) Theonelladins A-D, novel antineoplastic pyridine alkaloids from the Okinawan marine sponge *Theonella swinhoei*. *Tetrahedron Letters*, 30, 4833-4836; (b) Wang GYS, Kuramoto M, Uemura D, Yamada A, Yamaguchi K, Yazawa K. (1996) Three novel anti-microfouling nitroalkyl pyridine alkaloids from the Okinawan marine sponge *Callyspongia* sp. *Tetrahedron Letters*, 37, 1813-1816.
- [14] Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. (**1987**) Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from *Combretum caffrum. Journal of Natural Products*, **50**, 119-131.
- [15] Effenberger F, Jäger J. (1997) Synthesis of the adrenergic bronchodilators (R)-terbutaline and (R)-salbutamol from (R)-cyanohydrins. Journal of Organic Chemistry, 62, 3867-3873.
- [16] (a) De la Torre MC, García I, Sierra MA. (2002) Straightforward synthesis of the strong ambergris odorant γ-bicyclohomofarnesal and its endoisomer from R-(+)-sclareolide. *Tetrahedron Letters*, 43, 6351-6353; (b) Boukouvalas J, Wang JX, Marion O, Ndzi B. (2006) Synthesis and stereochemistry of the antitumor diterpenoid (+)-zerumin B. *Journal of Organic Chemistry*, 71, 6670-6673.
- [17] Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F. (1995) Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). Journal of Medicinal Chemistry, 38, 1666-1672.
- [18] Cheng YS, Liu WL, Chen SH. (1980) Pyridinium chlorochromate absorbed on alumina as a selective oxidant for primary and secondary alcohols [J]. *Synthesis*, 2, 223-224.
- [19] Yang Z. (2006) Synthesis and *in vitro* biological activity evaluation of the derivatives of combretastatin A-4. Letters in Drug Design & Discovery, 3, 544-546.
- [20] Arnó M, Betancur-Galvis LA, Sierra J, González MA, Zaragozá RJ. (2003) Synthesis and cytotoxic activity of novel C7-functionalized spongianed diterpenes. *Bioorganic & Medicinal Chemistry Letters*, 11, 3171-3177.
- [21] López-Lázaro M, Calderón-Montaño JM, Burgos-Morón E, Austin CA. (2011) Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide. *Mutagenesis*, 26, 489-498.
- [22] Prayong P, Barusrux S, Weerapreeyakul N, Prayong P, Barusrux S, Weerapreeyakul N. (2008) Cytotoxic activity screening of some indigenous Thai plants. *Fitoterapia*, 79, 598–601.
- [23] Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodríguez-Tudela JL. AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. (2003) Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, 9, 467-474.
- [24] National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. (2002) Approved Standard. National Committee for Clinical Laboratory Standards (NCCLS), document M38-A [ISBN 1-56238-470-8]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
- [25] Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, Pon S, Chapuis JC, Schmidt JM. (2009) E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. *Bioorganic & Medicinal Chemistry*, 17, 6606–6612.
- [26] Betancur-Galvis LA, Zuluaga C, Arnó M, González MA, Zaragoza RJ. (2002) Structure-activity relationship of cytotoxic effect on tumor cells and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes. Journal of Natural Products, 65, 189-192.

- [27] Agudelo-Gómez LS, Gómez Ríos GA, Durán García DC, Stashenko E, Betancur-Galvis L. (2010) Composición química y evaluación de la actividad antiherpética *in vitro* de aceites esenciales de *Lippia alba* (Mill) N.E. Brown y sus componentes mayoritarios. *Salud UIS*, *42*, 234-244.
- [28] Vlietinck AJ, Van Hoof L, Totté J, Lasure A, Vanden Berghe D, Rwangabo PC, Mvukiyumwami J. (1995) Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. *Journal of Ethnopharmacology*, 46, 31-47.
- [29] Kratz JM, Andrighetti-Fröhner CR, Kolling DJ, Leal PC, Cirne-Santos CC, Yunes RA, Nunes RJ, Trybala E, Bergström T, Frugulhetti IC, Barardi CR, Simões CM. (2008) Anti-HSV-1 and anti-HIV-1 activity of gallic acid and pentyl gallate. *Memórias do Instituto Oswaldo Cruz*, 103, 437-442.
- [30] Kratz JM, Andrighetti-Fröhner CR, Leal PC, Nunes RJ, Yunes RA, Trybala E, Bergström T, Barardi CR, Simões CM. (2008) Evaluation of anti-HSV-2 activity of gallic acid and pentyl gallate. *Biological & Pharmaceutical Bulletin*, 31, 903-907.

Muscone Exerts Neuroprotection in an Experimental Model of Stroke via Inhibition of the Fas Pathway Gang Wei, Dong-Feng Chen, Xiao-Ping Lai, Dong-Hui Liu, Ru-Dong Deng, Jian-Hong Zhou, Sai-Xia Zhang, Yi-Wei Li, Hui Li and Qiong-Dan Zhang	1069
Cytokinin and Auxin Effect on the Terpenoid Profile of the Essential Oil and Morphological Characteristics of Shoot Cultures of <i>Artemisia alba</i> Kalina Danova, Milka Todorova, Antoaneta Trendafilova and Liuba Evstatieva	1075
Variation in the Volatile Constituents of Different Plant Parts of <i>Ligusticopsis wallichiana</i> from Western Himalaya, India Rajendra C. Padalia, Ram S. Verma, Amit Chauhan, Chandan S. Chanotiya and Anju Yadav	1077
Determination of Chemical Constituents of Leaf and Stem Essential Oils of <i>Artemisia monosperma</i> from Central Saudi Arabia Merajuddin Khan, Ahmad A. Mousa, Kodakandla V. Syamasundar and Hamad Z. Alkhathlan	1079
Chemical Composition of the Essential Oils of <i>Centaurea formanekii</i> and <i>C. orphanidea</i> ssp. <i>thessala</i> , Growing Wild in Greece Mariem Ben Jemia, Carmen Formisano, Svetlana Bancheva, Maurizio Bruno and Felice Senatore	1083
Phytochemical Profiles of Volatile Constituents from <i>Centaurea ragusina</i> Leaves and Flowers and their Antimicrobial Effects Olivera Politeo, Mirjana Skocibusic, Ivana Carev, Franko Burcul, Igor Jerkovic, Mladenka Sarolic and Mladen Milos	1087
Chemical Composition and Antimicrobial Activity of Essential Oil of Different Parts of <i>Seseli rigidum</i> Mirjana Marčetić, Dragana Božić, Marina Milenković, Branislava Lakušić and Nada Kovačević	1091
Chemical Composition, Olfactory Analysis and Antibacterial Activity of <i>Thymus vulgaris</i> Chemotypes Geraniol, 4-Thujanol/Terpinen-4-ol, Thymol and Linalool Cultivated in Southern France Frich Schmidt Jürgen Wanner, Marting Höferl Leopold Jirovatz, Gerbard Buchbauer, Velizar Gochey, Tania Girova	
Albena Stoyanova and Margit Geissler	1095
Chemical Composition, Antimicrobial, Antioxidant and Cytotoxic Activity of Essential Oils of <i>Plectranthus cylindraceus</i> and <i>Meriandra benghalensis</i> from Yemen	
Nasser A. Awadh Ali, Martina Wurster, Annika Denkert, Norbert Arnold, Iman Fadail, Gamal Al-Didamony, Ulrike Lindequist, LudgerWessjohann and William N. Setzer	1099
Electrophysiological Responses of the <i>Naupactus bipes</i> Beetle to Essential Oils from Piperaceae Species Clécio S. Ramos, Marisi G. Soares, Adalberto M. da Silva, Luciane G. Batista-Pereira, Arlene G. Corrêa and Massuo J. Kato	1103
Inhibition of Essential Bacterial Peptidyl-tRNA Hydrolase Activity by Tropical Plant Extracts Hana McFeeters, Morgan J. Gilbert, Rachel M. Thompson, William N. Setzer, Luis R. Cruz-Vera, and Robert L. McFeeters	1107
<u>Review/Account</u>	

 Analytical Profiling of Bioactive Constituents from Herbal Products, using Metabolomics - A Review
 Nanjappan Satheeshkumar, Narayanan Nisha, Nirmal Sonali, Jayabalan Nirmal, Gaurav K. Jain, and Vudataneni Spandana
 1111

Natural Product Communications 2012

Volume 7, Number 8

Contents

<u>Original Paper</u>

Terpenoids from Cichorium intybus Chang-Xin Zhou, Li Zou, Zong-Zheng Zhao, Hong Zhu, Qiao-Jun He, Bo Yang and Li-She Gan	971
(6R,9S)-6"-(4"-Hydroxybenzoyl)-Roseoside, a New Megastigmane Derivative from <i>Ouratea polyantha</i> and its Effect on Hepatic Glucose-6-phosphatase Jairo Bermúdez, María Rodríguez, Masahisa Hasegawa, Freddy González-Muijca, Sandra Duque and Yojchiro Ito	973
The Cytotoxic Activity of Diterpenoids from Isodon species Ayumi Ohsaki, Masaaki Ozawa, Kanki Komiyama, Akio Kishida and Takahiko Isobe	977
Anti-proliferative Activity and Apoptotic Potential of Britannin, a Sesquiterpene Lactone from Inula aucheriana Maryam Hamzeloo Moghadam, Homa Hajimehdipoor, Soodabeh Saeidnia, Azadeh Atoofi, Roxana Shahrestani, Roger W. Read and Mahmoud Mosaddegh	979
Betulin as an Antitumor Agent Tested <i>in vitro</i> on A431, HeLa and MCF7, and as an Angiogenic Inhibitor <i>in vivo</i> in the CAM Assay Cristina Adriana Dehelean, Stefana Feflea, Judit Molnár, Istvan Zupko and Codruta Soica	981
Constituents of Twig Bark of Pear Cultivars (<i>Pyrus</i> species) Hideyuki Tomosaka, Hideaki Tamimoto, Yuki Tsukagoshi, Yasutsugu Suzuki, Hisako Ooka and Michiya Ota	987
Bio-assay Guided Isolation of α-Glucosidase Inhibitory Constituents from <i>Eclipta alba</i> Deepak Kumar, Raghuvir H. Gaonkar, Rina Ghosh and Bikas C. Pal	989
Chromolithic Method Development, Validation and System Suitability Analysis of Ultra-Sound Assisted Extraction of Glycyrrhizic Acid and Glycyrrhetinic Acid from Glycyrrhiza glabra Suphla Gupta, Rajni Sharma, Pankaj Pandotra, Sundeep Jaglan and Ajai Prakash Gupta	991
Furostanol Saponin and Diphenylpentendiol from the Roots of Asparagus racemosus BioDiversity Upendra Sharma, Neeraj Kumar and Bikram Singh BIODIVERSITy	995
Quinolizidine Alkaloids from Sophora velutina subsp. zimbabweensis (Fabaceae: Sophoreae) Erick Korir, Joyce J. Kiplimo, Neil R. Crouch, Nivan Moodley and Neil. A. Koorbanally	999
Flavonoids from the Japanese Monotypic Genus, <i>Nipponanthemum</i> Ayumi Uehara and Tsukasa Iwashina	1005
The Inhibitory Effects of Representative Chalcones Contained in Angelica keiskei on Melanin Biosynthesis in B16 Melanoma Cells Enos Tangke Arung, Shoko Furuta, Kazuhiro Sugamoto, Kuniyoshi Shimizu, Hiroya Ishikawa, Yoh-ichi Matsushita and Ryuichiro Kondo	1007
Flavonoid Constituents of <i>Pistacia integerrima</i> Zia Ullah, Rashad Mehmood, Muhammad Imran, Abdul Malik and Rehana A. Afzal	1011
Antioxidant and Anti-cholinesterase Activity of <i>Globularia meridionalis</i> Extracts and Isolated Constituents Rosa Tundis, Marco Bonesi, Federica Menichini, Monica R. Loizzo, Filomena Conforti, Giancarlo Statti, Filippo M. Pirisi and Eranaoaso Moniahini	1015
Antioxidant Activities and Total Phenolic and Flavonoid Contents in Three Indigenous Medicinal Vegetables of North-east India Jyotirekha G. Handique, Manas Pratim Boruah and Dipika Kalita	1013 SIS 1021
In Vitro Antiviral Activity of Heterophyllaea pustulata Extracts Brenda S. Konigheim, Mauricio Beranek, Laura R. Comini, Javier J. Aguilar, Juliana Marioni, José L. Cabrera, Marta S. Contigiani and Susana C. Núñez Montoya	1025
Re-investigation of the Anthraquinone Pool of <i>Rhamnus</i> spp.: Madagascin from the Fruits of <i>Rhamnus cathartica</i> and <i>R. intermedia</i> Francesco Epifano, Salvatore Genovese, Dario Kremer, Marco Randic, Giuseppe Carlucci and Marcello Locatelli	1029
Two New Phloroglucinol Derivatives and Five Photosensitizing Pheophorbides from Syzygium polyanthum Leaves (Salam) Lee Wei Har, Khozirah Shaari, Lee Hong Boon, Fadzly A. Kamarulzaman and Intan S. Ismail	1033
Production of <i>Curcuminoids</i> in Different <i>in vitro</i> Organs of <i>Curcuma longa</i> Laura Pistelli, Alessandra Bertoli, Federica Gelli, Laura Bedini, Barbara Ruffoni and Luisa Pistelli	1037
Two New Alkylresorcinols from <i>Homalomena wendlandii</i> and Their Cytotoxic Activity Luis A. Sánchez, Dionisio Olmedo, José Luis López-Pérez, Todd D. Williams and Mahabir P. Gupta	1043
Amides and an Alkaloid from <i>Portulaca oleracea</i> Tetsuo Kokubun, Geoffrey C. Kite, Nigel C. Veitch and Monique S. J. Simmonds	1047
Synthesis and Biological Evaluation of Combretastatin A-4 and Three Combretastatin-Based Hybrids Miguel A. González, David Pérez-Guaita, Lee S. Agudelo-Goméz, Verónica Tangarife-Castaño, Bibiana Zapata and Liliana Betancur-Galvis	1051
Two New <i>p</i> -Terphenyl Derivatives from the Marine Fungal Strain <i>Aspergillus</i> sp. AF119 Shao-Song Liu, Bao-Bing Zhao, Chun-Hua Lu, Jing-Jing Huang and Yue-Mao Shen	1 057
Quantitative Analysis of Fructo-oligosaccharides in <i>Gynura divaricata</i> subsp. <i>formosana</i> by High Performance Anion Exchange Chromatography–Pulsed Amperometric Detection Shen Chieh Chou and Shoai Sheng Lee	1062
Polyketide Metabolites from the Endophytic Fungus Microdiplodia sp. KS 75-1	1003
Yoshihito Shiono, Taiji Hatakeyama, Tetsuya Murayama and Takuya Koseki	1065

Continued inside backcover